A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Condition:   Gastroesophageal Junction Adenocarcinoma
Intervention:   Combination Product: apatinib XELOX radiotherapy
Sponsor:   Hebei Medical University
Not yet recruiting

http://ift.tt/2zsRxjH